ALGS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Aligos Therapeutics announced that the first participant was dosed in a Phase 1 study of ALG-170675, a potential best-in-class antisense oligonucleotide, by its partner Amoytop in ChinaAug 13, 2026
- Aligos Therapeutics completed enrollment in the Phase 2 B-SUPREME trial of Pevifoscorvir Sodium for chronic HBV infectionJul 13, 2026
- Aligos entered an exclusive licensing deal with Xiamen Amoytop to develop pevifoscorvir in Greater ChinaApr 17, 2026
- Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study of ALG-000184 in subjects with chronic HBV infectionAug 13, 2025
- Aligos Therapeutics presents positive data at the EASL Congress 2025.May 8, 2025